Hugues Le Bret

PayLead is bringing together daily banking and performance marketing for retailers with its proprietary technology fuelled by payment data. PayLead offers a unique opportunity for retail advertisers to address millions of consumers across Europe with unprecedented targeting capabilities. Since 2016 PayLead has changed the way consumers are experiencing loyalty by creating an effortless reward experience when they shop either online or in-store while turning payment data into value for marketers. PayLead operates over 25 loyalty programs for the largest retail banks, neo-banks, and consumer money apps in Europe. PayLead is headquartered in Paris and also holds offices in Madrid and Barcelona.

AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of Chemotherapy-Induced Peripheral Neuropathy, a common and painful side-effect of cancer treatments. It targets the signaling pathways involved in the regulation of pain by selectively inhibiting specific nociceptive sodium channel receptors. FDA granted ATX01 Fast-Track designation. The ACT study is an international Phase II randomized, placebo-controlled trial involving over 270 patients ; The results will be available in early 2025 and the company is making plans to expedite a Phase 3 trial. The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. In 2023, the company won France Biotech’s prestigious ESG HealthTech Trophy in recognition of its early commitment to ESG initiatives. For more information, see the company’s website

BNP Paribas Développement, filiale autonome du groupe bancaire international BNP Paribas, est une société anonyme qui investit directement ses fonds propres pour soutenir le développement des PME et ETI performantes et assurer leur pérennité en facilitant leur transmission, en qualité d’actionnaire minoritaire.

PayLead is bringing together daily banking and performance marketing for retailers with its proprietary technology fuelled by payment data. PayLead offers a unique opportunity for retail advertisers to address millions of consumers across Europe with unprecedented targeting capabilities. Since 2016 PayLead has changed the way consumers are experiencing loyalty by creating an effortless reward experience when they shop either online or in-store while turning payment data into value for marketers. PayLead operates over 25 loyalty programs for the largest retail banks, neo-banks, and consumer money apps in Europe. PayLead is headquartered in Paris and also holds offices in Madrid and Barcelona.

AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of Chemotherapy-Induced Peripheral Neuropathy, a common and painful side-effect of cancer treatments. It targets the signaling pathways involved in the regulation of pain by selectively inhibiting specific nociceptive sodium channel receptors. FDA granted ATX01 Fast-Track designation. The ACT study is an international Phase II randomized, placebo-controlled trial involving over 270 patients ; The results will be available in early 2025 and the company is making plans to expedite a Phase 3 trial. The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. In 2023, the company won France Biotech’s prestigious ESG HealthTech Trophy in recognition of its early commitment to ESG initiatives. For more information, see the company’s website

Nickel est un modèle alternatif de comptes sans découvert ouverts en 5 minutes chez un buraliste partenaire. Ce compte permet à nos clients de déposer et retirer de largent, faire des virements et des prélèvements grâce à un RIB remis dès louverture. Nous mettons à disposition de nos clients une carte internationale MasterCard à débit immédiat pour retirer du cash dans 1.8 millions de distributeurs en France et à létranger et payer ses achats chez 28 millions de commerçants dans 210 pays ou sur Internet. Quelques chiffres : - Plus de 3 000 000 clients depuis 2014 - 93% de clients satisfaits - Plus de 8 000 points de vente Nickel partenaires